Chicago Sun-TimesAbbVie to Buy Pharmacyclics to Expand In Cancer TherapyBloomberg(Bloomberg) -- AbbVie Inc. agreed to buy Pharmacyclics Inc. in a deal that gives it control of a blockbuster blood cancer therapy and values the smaller drugmaker at $21 billion. Under the terms of the transaction, AbbVie will pay $261.25 per share comprised ...AbbVie to buy cancer drug maker Pharmacyclics in $21 billion dealReutersAbbvie To Pay $21 Billion For Cancer Biotech PharmacyclicsForbesAbbVie to Buy Pharmacyclics in $21 Billion Deal -- UpdateNasdaqChicago Sun-Times -KDALall 11 news articles »